| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Rebecca M Craft, Julie A Marusich, Jenny L Wile. Sex differences in cannabinoid pharmacology: a reflection of differences in the endocannabinoid system? Life sciences. vol 92. issue 8-9. 2013-04-17. PMID:22728714. |
a greater understanding of the mechanisms underlying sexually dimorphic effects of cannabinoids will facilitate development of sex-specific approaches to treat marijuana dependence and to use cannabinoid-based medications therapeutically. |
2013-04-17 |
2023-08-12 |
Not clear |
| M F Lazenka, D E Selley, L J Sim-Selle. Brain regional differences in CB1 receptor adaptation and regulation of transcription. Life sciences. vol 92. issue 8-9. 2013-04-17. PMID:22940268. |
cannabinoid cb1 receptors (cb1rs) are expressed throughout the brain and mediate the central effects of cannabinoids, including Δ(9)-tetrahydrocannabinol (thc), the main psychoactive constituent of marijuana. |
2013-04-17 |
2023-08-12 |
Not clear |
| Melinda M Mulvihill, Daniel K Nomur. Therapeutic potential of monoacylglycerol lipase inhibitors. Life sciences. vol 92. issue 8-9. 2013-04-17. PMID:23142242. |
both cannabinoids, like marijuana, that exert anti-inflammatory action through stimulating cannabinoid receptors, and cyclooxygenase (cox) inhibitors, like aspirin, that suppress pro-inflammatory eicosanoid production have shown beneficial outcomes in mouse models of neurodegenerative diseases and cancer. |
2013-04-17 |
2023-08-12 |
mouse |
| Catherine A Newton, Thomas W Klei. Cannabinoid 2 (CB2) receptor involvement in the down-regulation but not up-regulation of serum IgE levels in immunized mice. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. vol 7. issue 3. 2013-04-10. PMID:22552780. |
marijuana cannabinoids such as Δ(9)-tetrahydrocannabinol (thc) have been shown in experimental systems to bias t helper immunity towards th2 and away from th1. |
2013-04-10 |
2023-08-12 |
mouse |
| Vincenzo Di Marzo, Luciano De Petrocelli. Why do cannabinoid receptors have more than one endogenous ligand? Philosophical transactions of the Royal Society of London. Series B, Biological sciences. vol 367. issue 1607. 2013-04-08. PMID:23108541. |
the endocannabinoid system was revealed following the understanding of the mechanism of action of marijuana's major psychotropic principle, Δ(9)-tetrahydrocannabinol, and includes two g-protein-coupled receptors (gpcrs; the cannabinoid cb1 and cb2 receptors), their endogenous ligands (the endocannabinoids, the best studied of which are anandamide and 2-arachidonoylglycerol (2-ag)), and the proteins that regulate the levels and activity of these receptors and ligands. |
2013-04-08 |
2023-08-12 |
human |
| Roger G Pertwe. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philosophical transactions of the Royal Society of London. Series B, Biological sciences. vol 367. issue 1607. 2013-04-08. PMID:23108552. |
three medicines that activate cannabinoid cb(1)/cb(2) receptors are now in the clinic: cesamet (nabilone), marinol (dronabinol; Δ(9)-tetrahydrocannabinol (Δ(9)-thc)) and sativex (Δ(9)-thc with cannabidiol). |
2013-04-08 |
2023-08-12 |
human |
| . Acute kidney injury associated with synthetic cannabinoid use--multiple states, 2012. MMWR. Morbidity and mortality weekly report. vol 62. issue 6. 2013-03-28. PMID:23407124. |
in march 2012, the wyoming department of health was notified by natrona county public health officials regarding three patients hospitalized for unexplained acute kidney injury (aki), all of whom reported recent use of synthetic cannabinoids (scs), sometimes referred to as "synthetic marijuana." |
2013-03-28 |
2023-08-12 |
Not clear |
| M Solinas, P Massi, A R Cantelmo, M G Cattaneo, R Cammarota, D Bartolini, V Cinquina, M Valenti, L M Vicentini, D M Noonan, A Albini, D Parolar. Cannabidiol inhibits angiogenesis by multiple mechanisms. British journal of pharmacology. vol 167. issue 6. 2013-03-25. PMID:22624859. |
the non-psychoactive cannabinoid cannabidiol (cbd) effectively inhibits the growth of different types of tumours in vitro and in vivo and down-regulates some pro-angiogenic signals produced by glioma cells. |
2013-03-25 |
2023-08-12 |
Not clear |
| Amanda L Baker, Louise K Thornton, Leanne Hides, Adrian Dunlo. Treatment of cannabis use among people with psychotic disorders: a critical review of randomised controlled trials. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716135. |
the development of cannabinoid agonist medication may be an effective strategy for cannabis dependence and suitable for people with psychotic disorders. |
2013-03-25 |
2023-08-12 |
Not clear |
| Sagnik Bhattacharyya, Zerrin Atakan, Rocio Martin-Santos, Jose A Crippa, Philip K McGuir. Neural mechanisms for the cannabinoid modulation of cognition and affect in man: a critical review of neuroimaging studies. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716136. |
this selective critical review focuses on the human neuroimaging studies investigating the effects of delta-9- tetrahydrocannabinol (thc) and cannabidiol (cbd), the two main cannabinoids of interest present in the extract of the cannabis plant. |
2013-03-25 |
2023-08-12 |
human |
| Sagnik Bhattacharyya, Zerrin Atakan, Rocio Martin-Santos, Jose A Crippa, Philip K McGuir. Neural mechanisms for the cannabinoid modulation of cognition and affect in man: a critical review of neuroimaging studies. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716136. |
these studies suggest that consistent with the polymorphic and heterogeneous nature of the effects of cannabis, thc and cbd have distinct and often opposing effects on widely distributed neural networks that include medial temporal and prefrontal cortex and striatum, brain regions that are rich in cannabinoid receptors and implicated in the pathophysiology of psychosis. |
2013-03-25 |
2023-08-12 |
human |
| Amir Englund, James M Stone, Paul D Morriso. Cannabis in the arm: what can we learn from intravenous cannabinoid studies? Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716141. |
cannabis in the arm: what can we learn from intravenous cannabinoid studies? |
2013-03-25 |
2023-08-12 |
Not clear |
| Jurgen Gallinat, Johannes Rentzsch, Patrik Rose. Neurophysiological effects of cannabinoids: implications for psychosis research. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716142. |
it is widely accepted that there is a close relationship between cannabis use, the endocannabinoid system, and psychosis. |
2013-03-25 |
2023-08-12 |
human |
| F Markus Lewek. Anandamide dysfunction in prodromal and established psychosis. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716147. |
it has been hypothesized nearly two decades ago that the ecb system may play a pathophysiological role in schizophrenia either in terms of an endogenous malfunction of the system itself and/or of a secondary malfunction as a result of the use of exogenous cannabinoids like Δ(9)-tetrahydrocannabinol, the major psychoactive phytocannabinoid in cannabis sativa. |
2013-03-25 |
2023-08-12 |
Not clear |
| Kerri A Schoedel, Sarah Jane Harriso. Subjective and physiological effects of oromucosal sprays containing cannabinoids (nabiximols): potentials and limitations for psychosis research. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716155. |
cannabis is made up of approximately 80 different cannabinoid compounds, which have synergistic or antagonistic effects on the principle active ingredient in cannabis, delta-9-tetrahydrocannabinol (thc). |
2013-03-25 |
2023-08-12 |
human |
| Aviv Segev, Shaul Lev-Ra. Neurocognitive functioning and cannabis use in schizophrenia. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716156. |
the effects of cannabis are mediated through the endocannabinoid system, which is a major regulator of neurotransmission and may be disturbed in schizophrenia. |
2013-03-25 |
2023-08-12 |
Not clear |
| Erica Zamberletti, Tiziana Rubino, Daniela Parolar. The endocannabinoid system and schizophrenia: integration of evidence. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716159. |
cannabis derivatives produce their cns effect through activation of the endocannabinoid system, a recently discovered signalling system comprising specific receptors, their intrinsic lipid ligands and the associated enzymatic machinery (transporters, biosynthetic and degradative enzymes). |
2013-03-25 |
2023-08-12 |
human |
| Erica Zamberletti, Tiziana Rubino, Daniela Parolar. The endocannabinoid system and schizophrenia: integration of evidence. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716159. |
another important aspect in studying the relationship between the endocannabinoid system and schizophrenia is the impact of cannabis consumption on psychotic disorders, especially when this occurs at vulnerable ages such as adolescence. |
2013-03-25 |
2023-08-12 |
human |
| What place for ▾ cannabis extract in MS? Drug and therapeutics bulletin. vol 50. issue 12. 2013-03-20. PMID:23241565. |
(5) cannabis extract containing delta9-tetrahydrocannabinol (dronabinol) and cannabidiol are the principal extracts from the cannabis plant present in a licensed preparation (▾sativex - gw pharma ltd), the first cannabinoid preparation to be approved for medical use. |
2013-03-20 |
2023-08-12 |
Not clear |
| E Ma Sánchez Robles, A Bagües Arias, Ma I Martín Fontelle. Cannabinoids and muscular pain. Effectiveness of the local administration in rat. European journal of pain (London, England). vol 16. issue 8. 2013-03-14. PMID:22354705. |
activation of cannabinoid (cb) receptors decreases nociceptive transmission in acute, inflammatory and neuropathic pain states; however, although the use of cannabis derivatives has been recently accepted as a useful alternative for the treatment of spasticity and pain in patients with multiple sclerosis, the effects of cb receptor agonists in muscular pain have hardly been studied. |
2013-03-14 |
2023-08-12 |
rat |